- Home
- VZLA vs COLL Comparison
VZLA vs COLL Comparison
Compare VZLA & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VZLA | COLL |
|---|---|---|
| Founded | 2017 | 2002 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | VZLA | COLL |
|---|---|---|
| Price | $3.25 | $23.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $49.00 |
| AVG Volume (30 Days) | ★ 3.9M | 768.9K |
| Earning Date | 09-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | N/A | $6.73 |
| Revenue Next Year | N/A | $1.37 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $2.88 | $21.43 |
| 52 Week High | $7.19 | $50.79 |
Technical Indicators
Market Signals| Indicator | VZLA | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 35.54 | 50.10 |
| Support Level | $3.21 | $21.54 |
| Resistance Level | $3.55 | $23.69 |
| Average True Range (ATR) | 0.14 | 0.66 |
| MACD | -0.05 | 0.32 |
| Stochastic Oscillator | 14.00 | 60.10 |
Price Performance
Historical ComparisonAbout VZLA Vizsla Silver Corp.
Vizsla Silver Corp is the exploration of mineral properties. The company currently conducts substantially all its operations in Canada and Mexico in one reportable segment. The company has one reportable segment, mainly mineral exploration, evaluation and development. Its project includes Panuco Project.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.